Pelthos
Freehold, US · Founded 2021 · 1 known investors
Find your way into Pelthos
Sign up to see every warm intro you have to Pelthos
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Pelthos team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Pelthos is a pharmaceutical company focused on commercializing therapeutic products for patients with unmet treatment needs, including skin health conditions.
Founders & leadership
FK
Francis KnuettelCEO and President, CFO, Treasurer and Secretary
EL
Eric LangChief Medical Officer
SP
Scott PleshaChief Executive Officer
JM
John M. GayChief Financial Officer, Treasurer and Secretary
RB
Richard BaxterNamed on SEC filing
PG
Peter GreenleafChairman
MP
Matthew PaulsNamed on SEC filing
AE
Andrew EinhornNamed on SEC filing
Board
EF
Ezra FriedbergBoard director
TD
Todd DavisBoard director
CS
Chia-Lin SimmonsBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$126.3M disclosed across 4 of 5 rounds · 2024–2026
▶$57.5MraisedNov 2026 · 7 investors · PharmaceuticalsRule 506(b)
▶$57.5MraisedNov 2026 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Scott PleshaExecutive Officer, Director
- John M. GayExecutive Officer
- Sai RangaraoExecutive Officer
- Richard BaxterDirector
- Peter GreenleafExecutive Officer, Director
- Ezra FriedbergDirector
- Todd DavisDirector
- Richard MalamutDirector
- Matthew PaulsDirector
- Andrew EinhornDirector
- Offering amount
- $57.5M
- Amount sold
- $57.5M
- First sale
- Oct 2026
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$18MraisedNov 2025 · 8 investors · PharmaceuticalsRule 506(b)
▶$18MraisedNov 2025 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Matthew PaulsDirector
- Peter GreenleafDirector
- Richard BaxterDirector
- Richard MalamutDirector
- Todd DavisDirector
- Francis Knuettel IIExecutive Officer
- Sai RangaraoExecutive Officer
- Scott PleshaExecutive Officer, Director
- Ezra FriedbergDirector
- Offering amount
- $18M
- Amount sold
- $18M
- First sale
- Nov 2025
- Incorporated
- Corporation, Nevada, 2021
- Federal exemptions
- 06b
▶$50.1MraisedJul 2025 · 13 investors · PharmaceuticalsRule 506(b)
▶$50.1MraisedJul 2025 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Matthew PaulsDirector
- Richard MalamutDirector
- Ezra FriedbergDirector
- Scott PleshaExecutive Officer, Director
- Sai RangaraoExecutive Officer
- Peter GreenleafDirector
- Francis Knuettel IIExecutive Officer
- Todd DavisDirector
- Richard BaxterDirector
- Offering amount
- $50.1M
- Amount sold
- $50.1M
- First sale
- Jul 2025
- Incorporated
- Corporation, Nevada, 2021
- Federal exemptions
- 06b
▶$30MofferedAug 2024 · 1 investors · PharmaceuticalsRule 506(b)
▶$30MofferedAug 2024 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ezra FriedbergDirector
- Chia-Lin SimmonsDirector
- Richard MalamutDirector
- Francis KnuettelExecutive Officer
- Eric LangExecutive Officer
- Todd DavisDirector
- Offering amount
- $30M
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$750KraisedAug 2024 · 1 investors · PharmaceuticalsRule 506(b)
▶$750KraisedAug 2024 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Francis KnuettelExecutive Officer
- Todd DavisDirector
- Ezra FriedbergDirector
- Richard MalamutDirector
- Chia-Lin SimmonsDirector
- Eric LangExecutive Officer
- Offering amount
- $750K
- Amount sold
- $750K
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Pelthos do?
- Pelthos is a pharmaceutical company focused on commercializing therapeutic products for patients with unmet treatment needs, including skin health conditions.
- Who are Pelthos's investors?
- Pelthos's investors include Ligand Pharmaceuticals.
- How much funding has Pelthos raised?
- Pelthos has disclosed $126.3M raised across 4 of its 5 known rounds.
- Where is Pelthos headquartered?
- Pelthos is headquartered in Freehold, US.
